Drug pricing in Europe, AI deals for VC firms, and more biotech news from The Readout

AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout

GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.

Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news

Johnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.

A combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.

Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.

RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news

The White House has used the program to reward companies that help its political goals.

Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout

Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.

New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout

Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout

Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.

Here is some of what you may have missed from the world's largest cancer research meeting.

We've been asking Medicare for weeks about the cost of giving seniors $50 obesity drugs.

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.

A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.

ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.

A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.

ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…

Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout

Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout